Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure

Detalhes bibliográficos
Autor(a) principal: Oliveira, Marta Iglis
Data de Publicação: 2018
Outros Autores: Souza Junior, Valter Romão de, Vidal, Claudia Fernanda de Lacerda, Araújo, Paulo Sérgio Ramos de
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/32364
Resumo: Universidade Federal de Pernambuco. Programa de Pós-graduação em Ciências da Saúde. Recife, PE, Brasil.
id CRUZ_b41e550c67bd61814f2d2fe066095579
oai_identifier_str oai:www.arca.fiocruz.br:icict/32364
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Oliveira, Marta IglisSouza Junior, Valter Romão deVidal, Claudia Fernanda de LacerdaAraújo, Paulo Sérgio Ramos de2019-04-04T14:03:51Z2019-04-04T14:03:51Z2018OLIVEIRA, M. I. et al. Virologic Suppression in Response to Antiretroviral Therapy despite Extensive Resistance within HIV-1 Reverse Transcriptase after the First Virologic Failure. BMC Infectious Diseases, v. 18, n. 1, p. 1-11, Oct. 2018.1471-2334https://www.arca.fiocruz.br/handle/icict/3236410.1186/s12879-018-3400-6engVirologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failureinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleUniversidade Federal de Pernambuco. Programa de Pós-graduação em Ciências da Saúde. Recife, PE, Brasil.Universidade Federal de Pernambuco. Faculdade de Medicina do Recife. Recife, PE, Brasil.Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil.Universidade Federal de Pernambuco. Programa de Pós-graduação em Ciências da Saúde. Recife, PE, Brasil / Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil.Background: Incomplete virologic suppression results in mutations associated with resistance and is a major obstacle to disease control. We analyzed the genotypic profiles of HIV-1 patients at the time of the first virologic failure and the response to a salvage regimen after 48 weeks. Methods: This work was a cross-sectional, retrospective, analytical study based on data collected from medical records and genotyping tests between 2006 and 2016. The sample consisted of data on individuals living with HIV (PLWH) from three major reference centers. Results: A total of 184 patients were included in the data analysis. Viral subtype B was the most common (81.3%) as well as M184 V/I (85.3%) and K103 codon mutations (65.8%). Forty-eight weeks after switching to a salvage regimen, 67.3% of patients achieved an undetectable viral load. Discussion: The number of mutations associated with nucleos(t)ide reverse transcriptase inhibitors (NRTI(t)s) did not affect virologic suppression (9.3% for zero NRTI(t)-associated mutations vs 48.6% for 1–2 NRTI(t)-associated mutations vs 42.1% for ≥3 NRTI(t)-associated mutations, p = 0.179). An ARV time (the beginning of the first ARV regimen up to genotyping) of > 36 months was a protective factor for detectable viral load (PR = 0.60, 95% CI = 0.39–0.92, p = 0.020) and a risk factor for developing ≥3 NRTI(t)-associated mutations (PR = 2.43, 95% CI 1.38–4.28, p = 0.002). Conclusions: We found that extensive resistance to NRTI(t)s at the time of the first virologic failure did not impact virologic suppression at 48 weeks after switching to a second-line therapy based on NRTI(t)s plus protease inhibitors.HIV-1 drug resistanceGenetic diversitySubtypesAntiretroviral therapyAdultoAnti-retrovirais / uso terapêuticoEstudos TransversaisResistência a Medicamentos Virais / genéticaFêmeaGenótipoInfecções por HIV / quimioterapiaTranscriptase Reversa do HIV / genéticaHIV-1 / genéticaHIV-1 / isolamento e purificaçãoHumanosMasculinoMeia idadeMutaçãoEstudos retrospectivosFatores de riscoTerapia de SalvamentoFalha no tratamentoCarga viralAdulto joveminfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83094https://www.arca.fiocruz.br/bitstream/icict/32364/1/license.txtee3692f7b0b97d5638099ab94397d05fMD51ORIGINALVirologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure.pdfVirologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure.pdfapplication/pdf698570https://www.arca.fiocruz.br/bitstream/icict/32364/2/Virologic%20suppression%20in%20response%20to%20antiretroviral%20therapy%20despite%20extensive%20resistance%20within%20HIV-1%20reverse%20transcriptase%20after%20the%20first%20virologic%20failure.pdfe5e15cf012d0461938a94e8b26ecae17MD52TEXTVirologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure.pdf.txtVirologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure.pdf.txtExtracted texttext/plain51546https://www.arca.fiocruz.br/bitstream/icict/32364/3/Virologic%20suppression%20in%20response%20to%20antiretroviral%20therapy%20despite%20extensive%20resistance%20within%20HIV-1%20reverse%20transcriptase%20after%20the%20first%20virologic%20failure.pdf.txt0b6813f3b71a73e97792afdbe4c7f6c8MD53icict/323642019-04-10 23:43:14.699oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352019-04-11T02:43:14Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure
title Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure
spellingShingle Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure
Oliveira, Marta Iglis
HIV-1 drug resistance
Genetic diversity
Subtypes
Antiretroviral therapy
Adulto
Anti-retrovirais / uso terapêutico
Estudos Transversais
Resistência a Medicamentos Virais / genética
Fêmea
Genótipo
Infecções por HIV / quimioterapia
Transcriptase Reversa do HIV / genética
HIV-1 / genética
HIV-1 / isolamento e purificação
Humanos
Masculino
Meia idade
Mutação
Estudos retrospectivos
Fatores de risco
Terapia de Salvamento
Falha no tratamento
Carga viral
Adulto jovem
title_short Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure
title_full Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure
title_fullStr Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure
title_full_unstemmed Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure
title_sort Virologic suppression in response to antiretroviral therapy despite extensive resistance within HIV-1 reverse transcriptase after the first virologic failure
author Oliveira, Marta Iglis
author_facet Oliveira, Marta Iglis
Souza Junior, Valter Romão de
Vidal, Claudia Fernanda de Lacerda
Araújo, Paulo Sérgio Ramos de
author_role author
author2 Souza Junior, Valter Romão de
Vidal, Claudia Fernanda de Lacerda
Araújo, Paulo Sérgio Ramos de
author2_role author
author
author
dc.contributor.author.fl_str_mv Oliveira, Marta Iglis
Souza Junior, Valter Romão de
Vidal, Claudia Fernanda de Lacerda
Araújo, Paulo Sérgio Ramos de
dc.subject.en.pt_BR.fl_str_mv HIV-1 drug resistance
Genetic diversity
Subtypes
Antiretroviral therapy
topic HIV-1 drug resistance
Genetic diversity
Subtypes
Antiretroviral therapy
Adulto
Anti-retrovirais / uso terapêutico
Estudos Transversais
Resistência a Medicamentos Virais / genética
Fêmea
Genótipo
Infecções por HIV / quimioterapia
Transcriptase Reversa do HIV / genética
HIV-1 / genética
HIV-1 / isolamento e purificação
Humanos
Masculino
Meia idade
Mutação
Estudos retrospectivos
Fatores de risco
Terapia de Salvamento
Falha no tratamento
Carga viral
Adulto jovem
dc.subject.decs.pt_BR.fl_str_mv Adulto
Anti-retrovirais / uso terapêutico
Estudos Transversais
Resistência a Medicamentos Virais / genética
Fêmea
Genótipo
Infecções por HIV / quimioterapia
Transcriptase Reversa do HIV / genética
HIV-1 / genética
HIV-1 / isolamento e purificação
Humanos
Masculino
Meia idade
Mutação
Estudos retrospectivos
Fatores de risco
Terapia de Salvamento
Falha no tratamento
Carga viral
Adulto jovem
description Universidade Federal de Pernambuco. Programa de Pós-graduação em Ciências da Saúde. Recife, PE, Brasil.
publishDate 2018
dc.date.issued.fl_str_mv 2018
dc.date.accessioned.fl_str_mv 2019-04-04T14:03:51Z
dc.date.available.fl_str_mv 2019-04-04T14:03:51Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv OLIVEIRA, M. I. et al. Virologic Suppression in Response to Antiretroviral Therapy despite Extensive Resistance within HIV-1 Reverse Transcriptase after the First Virologic Failure. BMC Infectious Diseases, v. 18, n. 1, p. 1-11, Oct. 2018.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/32364
dc.identifier.issn.pt_BR.fl_str_mv 1471-2334
dc.identifier.doi.none.fl_str_mv 10.1186/s12879-018-3400-6
identifier_str_mv OLIVEIRA, M. I. et al. Virologic Suppression in Response to Antiretroviral Therapy despite Extensive Resistance within HIV-1 Reverse Transcriptase after the First Virologic Failure. BMC Infectious Diseases, v. 18, n. 1, p. 1-11, Oct. 2018.
1471-2334
10.1186/s12879-018-3400-6
url https://www.arca.fiocruz.br/handle/icict/32364
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/32364/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/32364/2/Virologic%20suppression%20in%20response%20to%20antiretroviral%20therapy%20despite%20extensive%20resistance%20within%20HIV-1%20reverse%20transcriptase%20after%20the%20first%20virologic%20failure.pdf
https://www.arca.fiocruz.br/bitstream/icict/32364/3/Virologic%20suppression%20in%20response%20to%20antiretroviral%20therapy%20despite%20extensive%20resistance%20within%20HIV-1%20reverse%20transcriptase%20after%20the%20first%20virologic%20failure.pdf.txt
bitstream.checksum.fl_str_mv ee3692f7b0b97d5638099ab94397d05f
e5e15cf012d0461938a94e8b26ecae17
0b6813f3b71a73e97792afdbe4c7f6c8
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798325013630156800

Registros relacionados